Unlock instant, AI-driven research and patent intelligence for your innovation.

Amino acid compounds and methods of use

A compound, aminopyridine technology, applied in the field of therapeutic agents, can solve problems such as few treatment options

Pending Publication Date: 2021-07-30
PLIANT THERAPEUTICS INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Few treatment options are available as there are currently no options on the market with a demonstrated impact on long-term patient survival or symptomology

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amino acid compounds and methods of use
  • Amino acid compounds and methods of use
  • Amino acid compounds and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Synthetic example

[0745] The chemical reactions in the synthetic examples described can be readily adapted to prepare many other compounds of the invention, and alternative methods for preparing compounds of the invention are considered to be within the scope of the invention. For example, by modifications apparent to those skilled in the art (e.g. by suitably protecting interfering groups), by utilizing other suitable reagents known in the art than those described or by routine modification of the reaction conditions, Synthesis of non-exemplary compounds according to the invention can be successfully performed. Alternatively, other reactions disclosed herein or known in the art will be considered to have applicability for the preparation of other compounds of the invention. In the following examples, certain compounds are labeled as racemates, separated isomers, or have unassigned absolute stereochemistry at certain stereocenters, etc. For some compounds further separation of isomers and / or a...

example 1

[0746] Example 1, Compound 1

[0747] Two of N-(2-chloro-3-fluorobenzoyl)-O-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)homoserine kind of synthesis Example 1a

[0748]

[0749] Compound 1a-a: at 0 °C and under N 2 To a solution of tert-butyl 7-(4-hydroxybutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate (11 g, 35.90 mmol) in DMF (150 mL) NaH (2.15 g, 53.85 mmol, 60% suspension in mineral oil) was added. The mixture was stirred at 0°C for 30 minutes, and then 3-bromoprop-1-ene (5.21 g, 43.08 mmol, 1.2 equiv) was added to the mixture at 0°C. The mixture was stirred at 20°C for 10 hours. TLC (petroleum ether / ethyl acetate=3 / 1, R f = 0.1) indicated complete consumption of tert-butyl 7-(4-hydroxybutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate (11 g, 35.90 mmol). LCMS indicated detection of the desired M+H + . The mixture was treated with NH 4 The Cl solution was quenched and extracted with EtOAc (3 x 50 mL). The organic layer was washed with brine an...

example 2

[0768] Example 2, compound 8

[0769] 2-(2-Ethylbutanylamino)-5-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy)pentanoic acid

[0770]

[0771]Compound 2a: Two batches in parallel: To a mixture of ethyl 4-oxopentanoate (50 g, 346.82 mmol, 49.50 mL) and 2-aminopyridine-3-carbaldehyde (42.35 g, 346.82 mmol) in EtOH (800 mL) L-Proline (19.96 g, 173.41 mmol) was added. The mixture was refluxed at 85°C for 12 hours. LCMS indicated the reaction was complete. TLC (petroleum ether / ethyl acetate=2:1, R f =0.31) is the spot of the product. The mixtures were combined and concentrated under reduced pressure. H 2 O (1000 mL) and EtOAc (3 x 800 mL), washed with brine and washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was subjected to column chromatography (SiO 2 , petroleum ether / ethyl acetate=10 / 1 to 1:1) to obtain compound 2a (60 g, 240.85 mmol, 34.72% yield, 92.4% purity) as a yellow solid. LCMS(ESI+):m / z=231.1(M+H) + ,RT=...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
chiralityaaaaaaaaaa
chiralityaaaaaaaaaa
Login to View More

Abstract

The invention relates to compounds of formula (I), or a salt thereof, wherein R1, G, L1L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, [alpha]V[beta]1 integrin and [alpha]V[beta]6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IFF) and nonspecific interstitial pneumonia (NSTP).

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62 / 742,901, filed October 8, 2018, the entire contents of which are incorporated herein by reference. technical field [0003] The present disclosure generally relates to therapeutic agents useful as inhibitors of αvβ6 integrins. The therapeutic agents are useful in the treatment or prevention of fibrosis, such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). Background technique [0004] Fibrosis, a pathological feature of many diseases, results from a malfunction in the body's natural ability to repair damaged tissue. If left untreated, fibrosis can lead to scarring of vital organs, causing irreparable damage and eventual organ failure. [0005] Patients with nonalcoholic fatty liver disease (NAFLD) may progress from pure steatosis to nonalcoholic steatohepatitis (NASH) with subseq...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P1/16C07D213/74C07D241/06C07D471/04
CPCC07D471/04C07D519/00C07D493/08A61P11/00A61P1/16A61P9/00A61P13/12A61P17/00A61K31/4375A61P43/00
Inventor J·查M·穆诺茨M·莱利N·库珀K·莱夫特里斯D·J·小摩根斯T·霍姆郑亚军
Owner PLIANT THERAPEUTICS INC